Morimoto, Kenji
Yamada, Tadaaki http://orcid.org/0000-0002-6945-281X
Takeda, Takayuki
Shiotsu, Shinsuke
Date, Koji
Harada, Taishi
Tamiya, Nobuyo
Chihara, Yusuke
Takemura, Yoshizumi
Yamada, Takahiro
Kanda, Hibiki
Ishida, Masaki
Yoshimura, Akihiro
Iwasaku, Masahiro
Tokuda, Shinsaku
Kim, Young Hak
Takayama, Koichi
Article History
Accepted: 17 April 2023
First Online: 5 May 2023
Declarations
:
: Not applicable.
: Tadaaki Y received grants from Pfizer, Ono Pharmaceutical, Janssen Pharmaceutical, and Takeda Pharmaceutical and personal fees from Eli Lilly. KT received grants from Chugai Pharmaceutical and Ono Pharmaceutical, and personal fees from AstraZeneca, Chugai Pharmaceutical, MSD, Eli Lilly, Boehringer Ingelheim, and Daiichi Sankyo. The other authors have no conflicts of interest to declare.
: This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013), and the study protocol was approved by the institutional review board of Kyoto Prefectural University of Medicine (ERB-C-1580), and each participating hospital and was registered at the University Medical Hospital Information Network (UMIN) Clinical Trials Registry (UMIN000044048).
: All patients provided written informed consent.
: Not applicable
: The datasets generated during the current study are not publicly available because of ethical constraints but are available from the corresponding author upon reasonable request.
: Not applicable
: KM and Tadaaki Y contributed to the study conception and design. KM, TT, SS, KD, TH, NT, YC, YT, Takahiro Y, HK, and Masaki I obtained the clinical data. Data were interpreted by KM, Tadaaki Y, Masaki I, AY, Masahiro I, ST, YHK, and KT. The manuscript was prepared by KM, Tadaaki Y, and KT. The final version of the manuscript was read and approved by all the authors.